Esthesioneuroblastoma

The Johns Hopkins experience

Vicente Resto, David W. Eisele, Arlene Forastiere, Marianna Zahurak, Ding Jen Lee, William H. Westra

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

Background. Esthesioneuroblastoma (ENB) is an uncommon malignant neoplasm of the upper nasal cavity. Therapeutic management approaches for this neoplasm lack uniformity and there is no universally accepted staging system. Methods. A retrospective review of 27 patients with histologically confirmed ENB managed at The Johns Hopkins Hospital. Results. Eighty-five percent of patients had surgical resection as part of their disease management. Complete surgical resection was achieved in 62% of patients who had a craniofacial resection. Eighty percent of patients with negative surgical margins remain with no evidence of disease, with a median follow-up of 5.6 years. Adjuvant radiation therapy was beneficial to 62% of patients with positive surgical margins. Clinical responses were observed with cisplatin- and etoposide-containing chemotherapy regimens in patients with advanced disease. A revised staging system based on our experience is proposed. Conclusions. ENB is best managed by craniofacial resection with complete tumor resection. Adjuvant radiation therapy is warranted in patients that remain with positive histologic margins of resection. Chemotherapy with cisplatin- and etoposide-containing regimens may be useful for palliation of advanced disease. (C) 2000 John Wiley and Sons, Inc.

Original languageEnglish (US)
Pages (from-to)550-558
Number of pages9
JournalHead and Neck
Volume22
Issue number6
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Olfactory Esthesioneuroblastoma
Etoposide
Cisplatin
Radiotherapy
Drug Therapy
Neoplasms
Nasal Cavity
Disease Management

Keywords

  • Chemotherapy
  • Craniofacial resection
  • Esthesioneuroblastoma
  • Radiation therapy
  • Tumor staging

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Resto, V., Eisele, D. W., Forastiere, A., Zahurak, M., Lee, D. J., & Westra, W. H. (2000). Esthesioneuroblastoma: The Johns Hopkins experience. Head and Neck, 22(6), 550-558. https://doi.org/10.1002/1097-0347(200009)22:6<550::AID-HED2>3.0.CO;2-0

Esthesioneuroblastoma : The Johns Hopkins experience. / Resto, Vicente; Eisele, David W.; Forastiere, Arlene; Zahurak, Marianna; Lee, Ding Jen; Westra, William H.

In: Head and Neck, Vol. 22, No. 6, 2000, p. 550-558.

Research output: Contribution to journalArticle

Resto, V, Eisele, DW, Forastiere, A, Zahurak, M, Lee, DJ & Westra, WH 2000, 'Esthesioneuroblastoma: The Johns Hopkins experience', Head and Neck, vol. 22, no. 6, pp. 550-558. https://doi.org/10.1002/1097-0347(200009)22:6<550::AID-HED2>3.0.CO;2-0
Resto, Vicente ; Eisele, David W. ; Forastiere, Arlene ; Zahurak, Marianna ; Lee, Ding Jen ; Westra, William H. / Esthesioneuroblastoma : The Johns Hopkins experience. In: Head and Neck. 2000 ; Vol. 22, No. 6. pp. 550-558.
@article{9f521fac013a4f5bb546f93a041799ac,
title = "Esthesioneuroblastoma: The Johns Hopkins experience",
abstract = "Background. Esthesioneuroblastoma (ENB) is an uncommon malignant neoplasm of the upper nasal cavity. Therapeutic management approaches for this neoplasm lack uniformity and there is no universally accepted staging system. Methods. A retrospective review of 27 patients with histologically confirmed ENB managed at The Johns Hopkins Hospital. Results. Eighty-five percent of patients had surgical resection as part of their disease management. Complete surgical resection was achieved in 62{\%} of patients who had a craniofacial resection. Eighty percent of patients with negative surgical margins remain with no evidence of disease, with a median follow-up of 5.6 years. Adjuvant radiation therapy was beneficial to 62{\%} of patients with positive surgical margins. Clinical responses were observed with cisplatin- and etoposide-containing chemotherapy regimens in patients with advanced disease. A revised staging system based on our experience is proposed. Conclusions. ENB is best managed by craniofacial resection with complete tumor resection. Adjuvant radiation therapy is warranted in patients that remain with positive histologic margins of resection. Chemotherapy with cisplatin- and etoposide-containing regimens may be useful for palliation of advanced disease. (C) 2000 John Wiley and Sons, Inc.",
keywords = "Chemotherapy, Craniofacial resection, Esthesioneuroblastoma, Radiation therapy, Tumor staging",
author = "Vicente Resto and Eisele, {David W.} and Arlene Forastiere and Marianna Zahurak and Lee, {Ding Jen} and Westra, {William H.}",
year = "2000",
doi = "10.1002/1097-0347(200009)22:6<550::AID-HED2>3.0.CO;2-0",
language = "English (US)",
volume = "22",
pages = "550--558",
journal = "Head and Neck Surgery",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Esthesioneuroblastoma

T2 - The Johns Hopkins experience

AU - Resto, Vicente

AU - Eisele, David W.

AU - Forastiere, Arlene

AU - Zahurak, Marianna

AU - Lee, Ding Jen

AU - Westra, William H.

PY - 2000

Y1 - 2000

N2 - Background. Esthesioneuroblastoma (ENB) is an uncommon malignant neoplasm of the upper nasal cavity. Therapeutic management approaches for this neoplasm lack uniformity and there is no universally accepted staging system. Methods. A retrospective review of 27 patients with histologically confirmed ENB managed at The Johns Hopkins Hospital. Results. Eighty-five percent of patients had surgical resection as part of their disease management. Complete surgical resection was achieved in 62% of patients who had a craniofacial resection. Eighty percent of patients with negative surgical margins remain with no evidence of disease, with a median follow-up of 5.6 years. Adjuvant radiation therapy was beneficial to 62% of patients with positive surgical margins. Clinical responses were observed with cisplatin- and etoposide-containing chemotherapy regimens in patients with advanced disease. A revised staging system based on our experience is proposed. Conclusions. ENB is best managed by craniofacial resection with complete tumor resection. Adjuvant radiation therapy is warranted in patients that remain with positive histologic margins of resection. Chemotherapy with cisplatin- and etoposide-containing regimens may be useful for palliation of advanced disease. (C) 2000 John Wiley and Sons, Inc.

AB - Background. Esthesioneuroblastoma (ENB) is an uncommon malignant neoplasm of the upper nasal cavity. Therapeutic management approaches for this neoplasm lack uniformity and there is no universally accepted staging system. Methods. A retrospective review of 27 patients with histologically confirmed ENB managed at The Johns Hopkins Hospital. Results. Eighty-five percent of patients had surgical resection as part of their disease management. Complete surgical resection was achieved in 62% of patients who had a craniofacial resection. Eighty percent of patients with negative surgical margins remain with no evidence of disease, with a median follow-up of 5.6 years. Adjuvant radiation therapy was beneficial to 62% of patients with positive surgical margins. Clinical responses were observed with cisplatin- and etoposide-containing chemotherapy regimens in patients with advanced disease. A revised staging system based on our experience is proposed. Conclusions. ENB is best managed by craniofacial resection with complete tumor resection. Adjuvant radiation therapy is warranted in patients that remain with positive histologic margins of resection. Chemotherapy with cisplatin- and etoposide-containing regimens may be useful for palliation of advanced disease. (C) 2000 John Wiley and Sons, Inc.

KW - Chemotherapy

KW - Craniofacial resection

KW - Esthesioneuroblastoma

KW - Radiation therapy

KW - Tumor staging

UR - http://www.scopus.com/inward/record.url?scp=0033844922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033844922&partnerID=8YFLogxK

U2 - 10.1002/1097-0347(200009)22:6<550::AID-HED2>3.0.CO;2-0

DO - 10.1002/1097-0347(200009)22:6<550::AID-HED2>3.0.CO;2-0

M3 - Article

VL - 22

SP - 550

EP - 558

JO - Head and Neck Surgery

JF - Head and Neck Surgery

SN - 1043-3074

IS - 6

ER -